Gaucher disease is caused by an inherited deficiency of glucocerebrosidase, inducing accumulation of glucocerebroside within macrophages of the reticuloendothelial system. Type I, the non-neuroneopathic form is most common, and has a predilection among Ashkenazi Jews. Phenotypic heterogeneity is well-documented: patients may present with hepatosplenomegaly, hypersplenism, and skeletal or pulmonary complications, or may be totally asymptomatic. Intravenous enzyme replacement therapy effectively reduces organomegaly and improves haematological parameters (Barton et al, 1991) .
Both untreated milder patients as well as those treated with enzyme, often complain of fatigue and weakness. As of 1995, vitamin B 12 levels were monitored during follow-up visits in our clinic of more than 400 patients. Among a cohort of 148 adult, type I, Ashkenazi Jewish patients, 43´8% had low serum levels (, 200 ng/l) of vitamin B 12 (Gielchinsky et al, 1997) . This prompted a large-scale study among untreated patients with Gaucher disease relative to Ashkenazi Jewish neighbour-controls. An unexpectedly high prevalence of low serum vitamin B 12 was noted in both groups and, therefore, a group of healthy blood donors of various ethnicities were investigated.
PATIENTS AND METHODS
All adult patients (. 18 years) with type I Gaucher disease, who were not treated with enzyme, or with B 12 supplementation in the previous year, were asked to participate. For each patient, two neighbour-controls were chosen by that patient's physician from his patient roster. An age-(^5 years) and sex-matched control who was Ashkenazi Jewish but unrelated to the patient was chosen from the names above and below that of the patient. The neighbourcontrols were also considered matched with reference to socio-economic factors.
Vitamin B 12 levels were measured by two different analysers (Axsym-Abbott Diagnostics, Abbott Paire, IL, USA, and Access-Sanofi Pasteur System, France); the correlation was nearly symmetrical. Total run coefficient of variation was , 10% at levels . 200 ng/l, and up to 15% at , 150 ng/l. A third analysis performed at the UC Davis Medical Center, Sacramento, CA, USA, confirmed the above.
Homocysteine (HCY) and methymalonic acid (MMA) were determined by standard methods (Jacobsen et al, 1994) using frozen sera. HCY . 15 mmol/l and MMA . 350 nmol/l were considered outside the normal range.
Blood donor volunteers at various geographical locations of the National Blood Services of Israel were asked to donate an additional sample for this study. Inclusion in an ethnic group was predicated on both parents being of the same ethnicity.
All participants were requested to complete a demographics questionnaire about dietary habits, i.e. being vegetarian, cigarette smoking, use of multivitamins, and food supplements.
All phases of the study were approved by the Shaare Zedek Medical Centre Institutional Review Board (IRB), as well as by the National Blood Services.
Statistical analysis. For continuous variables, the paired ttest and one-sample t-test were applied to test significance of change and the hypothesis that the change was of a given magnitude respectively. The Pearson and Spearman correlation coefficients were calculated to assess the association between continuous variables.
The chi-square test and Fisher's exact tests were used for comparisons between groups for qualitative variables. To assess a change in qualitative dichotomous variables, the McNemar test was applied.
RESULTS
Among untreated patients, there were 89 patients whose family practitioner provided 122 neighbour-controls (68´5% compliance). There was no statistically significant difference in demographics (data not shown). There was no statistically significant difference with reference to incidence of low serum B 12 concentrations, 40% and 31% respectively (Table I) .
There was no statistically significant difference when comparing elevated HCY levels (. 15 mmol/l) with vitamin B 12 levels (Table I ) among untreated patients (28%) and neighbour-controls (24%). MMA assays were performed on 32 samples in each group: 16 samples with B 12 levels , 200 ng/l (i.e. presumed low) and 16 samples with B 12 levels . 200 ng/l (i.e. presumed normal). Elevated MMA values (. 350 nmol/l) were inversely correlated with B 12 levels: 29% in untreated patients and 19% in neighbour-controls, which was not statistically significant. Non-parametric analysis was also not statistically significant.
There were 1512 blood samples drawn from blood donors; in 720 cases, both parents were of the same ethnicity (Table II) . All routine haematological parameters were within the normal range, but a . 12% prevalence of low vitamin B 12 levels (Table II) was noted in all groups.
DISCUSSION
Many non-specific symptoms of vitamin B 12 deficiency are not unique to patients with Gaucher disease; these include subjective complaints such as malaise and fatigue, but also cognitive deficits (memory loss, irritability, and mood swings); gastrointestinal complications; patchy hyperpigmentation; and even reproductive problems, such as infertility (Stabler et al, 1990) . The common finding of macrocytosis in Gaucher disease and the presence of symptoms, particularly fatigue unaffected by enzyme replacement therapy, underscored the need for assessment of vitamin B 12 levels.
Untreated patients were chosen to minimize the confounding effects of enzyme treatment (although biasing towards milder patients). The incidence of low serum vitamin B 12 in untreated patients was surprising, but similar findings among healthy Ashkenazi Jewish control subjects were unexpected.
Methodological bias was theoretically minimal as attested to by excellent correlation of various assays, inverse correlation between vitamin B 12 and metabolites, and the fact that paediatric patients with Gaucher disease do not have low serum B 12 (data not presented).
Screening of multiethnic healthy blood donors was undertaken to ascertain whether low serum B 12 among Ashkenazi Jews reflects a genetic predisposition or an environmental factor in Israel. While racial differences have been previously reported, the prevalence was far lower (Saxena & Carmel, 1987) . Moreover, even among patients with dementia/psychosis (Carney & Sheffield, 1978) , older adults (Ho et al, 1999) , and Kenyan patients with megaloblastic anaemia (Mwanda & Dave, 1999) , the incidence of vitamin B 12 deficiency was well below 10%.
The results of our studies merit cautious analysis in that all the healthy subjects with low B 12 levels were asymptomatic. However, because homocysteinaemia in itself is a well-recognized risk factor for cardiovascular diseases, the results in the healthy cohort merit attention. Issues of population screening, food fortification (Zeitlin et al, 1997; Czeizel & Merhala, 1998) and serological testing for pernicious anaemia or Schilling tests, as well as (prophylactic) treatment in those with elevated HCY (Sozen et al, 1998) , should be addressed.
In conclusion, therefore, more studies are required. To ignore this very real health problem in a multi-ethnic population by re-defining the lower range of normal vitamin B 12 values would be inappropriate. Our recommendation is that cooperative efforts be initiated among Mediterranean Basin nations as an environmental modifier may encompass more than the small geographical area that Israel represents and, hence, may exert similar effects in neighbouring countries.
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